Original ArticlesSynthesis, radiolabeling, and biodistribution of putative metabolites of iodoazomycin arabinoside (cas 138172-12-0)

Add time:08/17/2019    Source:sciencedirect.com

Scintigraphic evaluation of patients with advanced oncological disease showed uptake of radioactivity in the brain following administration of the hypoxic imaging agent 123I-iodoazomycin arabinoside (123I-IAZA). Three proposed metabolites of IAZA—methyl 5-deoxy-5-iodo-D-arabinofuranoside, methyl 2,3-di-O-acetyl-5-deoxy-5-iodo-α-D-arabinofuranoside, and 1-(5-deoxy-5-iodo-α-D-arabinofuranosyl)-2-aminoimidazole (IAIA)—were synthesized, radiolabeled with 125I, and investigated in normal and tumor-bearing murine models for their contribution to this unusual phenomenon. The three compounds were readily radiolabeled by melt or solvent exchange procedures. Biodistribution data indicated rapid blood clearance, rapid excretion, and little tissue accumulation in the brain. IAIA showed significant tumor to blood ratios at 4 h (4.3:1) and liver to blood ratios at 24 h (30:1).

We also recommend Trading Suppliers and Manufacturers of iodoazomycin arabinoside (cas 138172-12-0). Pls Click Website Link as below: cas 138172-12-0 suppliers

Prev:Novel thermo-responsive micelles prepared from amphiphilic hydroxypropyl METHYL CELLULOSE (cas 138169-43-4)-block-JEFFAMINE copolymers
Next:[131I]iodoazomycin arabinoside (cas 138172-12-0) for low-dose-rate isotope radiotherapy: radiolabeling, stability, long-term whole-body clearance and radiation dosimetry estimates in mice)